inhibit Apo(a) gene transcription. 1, 13 Few human studies have looked at Lp(a) metabolism in untreated healthy volunteers, 14 but, to date, there have been no human studies characterizing the effects of ERN on Lp(a) metabolism. New analytical methods based on liquid chromatography-tandem mass spectrometry and enzymatic proteolysis have simplified the study of apolipoprotein kinetics in humans. [15] [16] [17] In this study, we applied these approaches to analyze the effects of ERN on Apo(a) metabolism in 8 hypertriglyceridemic patients.
Materials and Methods
Eight nondiabetic, overweight male subjects (aged 48±12 years; body mass index, 31.2±1.8 kg/m 2 ; waist circumference, 106±4.9 cm) with hypertriglyceridemia (triglycerides, 226±78 mg/dL) were enrolled in a randomized crossover controlled study (8 weeks/phase and a 4-week washout interval) comparing 2 g/day ERN (gradually increased from 0.5 to 2.0 g/day in the first 4 weeks to avoid flushing effects and associated in both arms with 300 mg/day of lysine acetylsalicylate) with placebo. Plasma lipids and lipoproteins, as well as lipoprotein kinetics, were assessed as described in detail in the supplemental Materials and Methods section available in the online-only Data Supplement.
Results
Overall, ERN treatment was well tolerated and no dropout or major flushes were observed. A small and nonsignificant increase of fasting blood glucose and insulin concentrations were observed with ERN (not shown) as well as HOMA-IR index (3.8±3.7 versus 5.6±2.7, NS) Compared with placebo, 
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ERN decreased plasma triglycerides by 46% (118±62 versus 221±67 mg/dL; P=0.023), total cholesterol by 16% (180±38 versus 215±49 mg/dL; P=0.008), LDL-C by 20% (103±29 versus 128±45 mg/dL; P=0.039), ApoB100 by 22% (81±22 versus 104±29 mg/dL; P=0.008), and Apo(a) by 20% (44±14 versus 54±15 nmol/L; P=0.008; Table) . In contrast, ERN raised high-density lipoprotein cholesterol by 20% (49±10 versus 41±13 mg/dL; P=0.008) but did not increase apolipoprotein A-I concentrations (136±15 versus 131±24 mg/ dL; P=0.531; Table) . The dominant isoform size of Apo(a) ranged from 12 to 18 KIV repeats (Table) . The average size of Apo(a) was slightly modified in 3 subjects (6%-10%). Plasma PCSK9 concentrations were decreased by 29% with ERN (180±53 versus 260±70 ng/mL; P=0.008; (Table) . ERN affected the mean 2 H 3 -Leucine incorporation during the course of the tracer infusion for Apo(a) (P<0.05; Figure 1 ). Compared with placebo, ERN decreased the fractional catabolic rate (FCR) of Apo(a) by 37% (0.36±0.19 versus 0.58±0.28 pool/d; P=0.008), whereas no significant change was observed in ApoB100-VLDL ( Figure 2 ), and a slight increase of ApoB100-LDL FCR was shown (+12%; P=0.031; 1-tailed). ERN treatment also reduced the Apo(a) production rate by 50% compared with placebo (0.7±0.4 versus 1.4±0.8 nmol/kg per day; P=0.008) but had no significant effects on ApoB100-VLDL or ApoB100-LDL production rates ( Figure 2 ). Apo(a) FCRs and production rates were significantly correlated (P<0.0001; r=0.8223) suggesting that these 2 processes are under control of similar pathways. No significant correlations were observed between ApoB100 plasma concentrations and Apo(a) kinetic data. Similarly, no significant correlation was observed between HOMA-IR index or changes in PCSK9 plasma concentrations and Apo(a) catabolic rates.
Discussion
The new liquid chromatography-tandem mass spectrometry method used in this study enabled analysis of in vivo effects of ERN on Apo(a) metabolism in hypertriglyceridemic subjects. As expected, ERN significantly decreased triglycerides and Apo(a) and ApoB100 plasma concentrations and raised high-density lipoprotein cholesterol. Apo(a) production and catabolic rates were significantly reduced, while no significant changes were observed in ApoB100-VLDL kinetics. An increase in ApoB100-LDL catabolism was shown, which may be related to the significant decrease of PCSK9 plasma concentrations.
Because of high discrepancies in plasma concentrations and complexity of size determination, conventional analytical methods 18, 19 are not relevant for Apo(a) measurements. 11, 16, 17 This study confirmed that enzymatic proteolysis and subsequent liquid chromatography-tandem mass spectrometry analysis of specific peptides overcome these difficulties (Materials and Methods section in the online-only Data Supplement). [15] [16] [17] Our results are in agreement with a study using similar methods and a single compartment model to analyze Apo(a) metabolism in 3 healthy subjects 16 and to other data reported in a using gas chromatographymass spectrometry study and a multicompartment modeling. 20 Together, these comparisons validated our analytic method and the mono compartmental model we have used. Compared with studies in healthy subjects without dyslipidemias, this study showed that hypertriglyceridemia does not have a strong effect on Apo(a) kinetics, although data are in near the upper limits of the reported normal range. 20 We were also amazed to observe a slight decrease of size of Apo(a) in few subjects with ERN treatment. This was probably because of a slight change in the proportion of the 2 isoforms related to unknown effects of ERN or more likely to the tolerated precision of the liquid chromatography-tandem mass spectrometry method (±15%) and the small number of patients.
This study showed that ERN was able to significantly decrease Apo(a) production rates by 50%, consistent with in vitro studies revealing the impacts of ERN on Apo(a) hepatic production and on ApoB100 availability for Lp(a) synthesis. 21 Nicotinic acid is already known to inhibit hepatocyte diacylglycerol acyltransferase-2, a key enzyme for triglyceride synthesis, accelerating intracellular hepatic ApoB100 degradation and decreasing hepatic ApoB100-VLDL and ApoB100-LDL secretion rates. 21 Other studies have shown that nicotinic acid increased retention of Apo(a) at the hepatocyte surface and also directly inhibited transcription of the Apo(a) gene. 1, 13 This study did not show any association between ApoB100-LDL or ApoB100-VLDL and Apo(a) production rate, in agreement with a previous kinetic study of untreated healthy controls having showed that the kinetics of Apo(a)-Lp(a) were similar to ApoB100-Lp(a) but not to ApoB100-VLDL or ApoB100-LDL. 20 The modification of Apo(a) production rate by ERN could thus be a consequence of an inhibition of Apo(a) transcription or a decrease of protein release as discussed above. In addition, ERN did not show significant changes on ApoB100 kinetic parameters in VLDL as previously reported by Lamon-Fava et al. 22 Conversely, Fabbrini et al 23 have found a significant effect of ERN to reduce VLDL-ApoB100 production rates but the different metabolic states of patients (hepatic steatosis) and the longer duration of treatment (16 weeks) could explain these differences.
Results also showed that ERN was able to significantly decrease the rate of Apo(a) catabolism by 37%, which partially compensated for the change in production rates in the liver. Although catabolic mechanisms of Lp(a) are poorly understood, kidneys seem to play central roles involving binding with megalin/glycoprotein 330. 24 In patients with advanced chronic kidney diseases, elevated plasma Lp(a) concentrations were observed, 25 which were related to decreases in Apo(a) and ApoB100 Lp(a) catabolic rates. 26 It has also been shown that, in patients with chronic kidney diseases, ENR has reduced efficacy. 27 In addition to the kidney, other mechanisms are likely to occur in the liver. Indeed, Lp(a) metabolism has been linked to the scavenger receptor class B type I, 28 the low-density lipoprotein receptor-related protein 1, the very low-density lipoprotein receptor, plasminogen receptors, and megalin/ glycoprotein 330. 24 The role of the LDL receptor on Lp(a) catabolism is controversial. A recent study in HepG2 cells provided evidence that the LDL receptor is implicated in Lp(a) catabolism modulated by PCSK9. 29 Our data do not support this finding as we showed a significant decrease in ApoB100 plasma concentrations (−22%) probably related to the increase of ApoB100-LDL catabolism (+12%) possibly as a consequence of the decrease in PCSK9 plasma concentrations known to occur with ERN. 30, 31 The increase of ApoB100-LDL FCR suggested an enhanced the LDL receptor activity and an increase of Apo(a) catabolism was expected from the HepG2 cell experiment. 29 We have observed just the opposite but it is possible that the role of the LDL receptor in Lp(a) catabolism could have been overshadowed by changes in other Lp(a) catabolic pathways related to ERN as we measured the total in vivo disappearance. In addition, no significant relationship was observed between changes of Apo(a) FCR and PCSK9 plasma concentrations (P=0.2436; r=0.4668), which do not support a central role of PCSK9 in Apo(a) catabolism.
This study has some limitations. To follow the guidelines of ERN prescription, only patients with hypertriglyceridemia were selected. Although unlikely, it is not possible to rule out that different results could have been observed in lean normolipidemic subjects. It is also difficult to anticipate the mechanisms involved in patients with elevated baseline Lp(a) and the effect of ERN in these individual. We were not able to get a good recovery of Lp(a) in the ApoB100 containing particles. Then, we only present Apo(a) kinetics as a whole and not the fine tuning and exchanges of Lp(a) related to measured activities of lipases or transfer proteins. However, this simple approach allows to get new information on the mechanisms involved in the decrease of plasma Lp(a) related to ERN treatment and could initiated new researches. Finally, this study was performed in men with no statin treatment and it is not known if the sex or an added treatment could have changed the results.
In conclusion, decreased plasma Lp(a) in ERN-treated patients was related to a decrease of Apo(a) production rate, which was partially compensated by decreased catabolism. The regulatory mechanisms involved in changes of both production and catabolism of Apo(a) by ERN seem to be connected. No cardiovascular benefits of ERN were reported in recent cardiovascular outcome trials but with a decrease of plasma Lp(a) of only 20%. [32] [33] [34] [35] A better understanding of the mechanisms responsible for decreased Lp(a) catabolism associated with ERN treatment could help the development of new derived niacin treatments targeting only the production rate leading to a more effective therapy for lowering Lp(a) plasma concentrations.
